Vyvanse in Adults 65 and Older: Geriatric and Developmental Impact

Why Age Changes Everything About Lisdexamfetamine

Lisdexamfetamine itself is pharmacologically inert. After oral ingestion, hydrolysis by red-blood-cell peptidases converts it to the active moiety d-amphetamine plus l-lysine. The rate and completeness of that conversion are largely preserved with aging, but what happens next is substantially different in a 70-year-old compared with a 35-year-old. Renal clearance of d-amphetamine drops predictably with age, cardiovascular reserve narrows, and polypharmacy risk climbs. [1]

Pharmacokinetic Changes in Older Adults

Renal function declines at roughly 0.75 to 1 mL/min/1.73 m² per year after age 40. By age 70, the average patient has lost 25 to 35% of peak GFR. Because d-amphetamine is predominantly renally excreted, even moderate chronic kidney disease extends its effective half-life well beyond the 10 to 13 hours seen in younger adults with normal renal function. The FDA label for Vyvanse caps the maximum daily dose at 30 mg for patients with severe renal impairment (eGFR <15 mL/min/1.73 m²) and 50 mg for moderate impairment, reflecting this directly. [2]

Urinary pH also shifts with age-related dietary changes and common medications. Alkaline urine from antacid use or thiazide therapy reduces tubular reabsorption of amphetamine and raises plasma levels, while acidic urine does the opposite. These interactions are rarely flagged during a typical geriatric medication review.

Volume of Distribution and Body Composition

Older adults carry proportionally less lean body mass and total body water. Amphetamines are moderately lipophilic, so the apparent volume of distribution may decrease, raising peak plasma concentrations for a given dose. A 20 mg dose in a 68 kg, 72-year-old woman could produce meaningfully higher peak d-amphetamine levels than the same dose in a 90 kg, 40-year-old man, even before renal differences are considered. The FDA-approved prescribing information confirms that no dedicated pharmacokinetic study has been conducted in patients 65 and older. [3]

Cardiovascular Risk in the Geriatric Population

Cardiovascular disease is the primary cause of death in adults over 65 in the United States, affecting roughly 70% of that population according to CDC data. Introducing a sympathomimetic agent into this group requires explicit quantification of risk, not just a general warning. [4]

Blood Pressure and Heart Rate Effects

Across the adult key trials for Vyvanse, mean increases in systolic blood pressure were 1.2 to 1.7 mmHg and mean heart rate increases were 2.0 to 2.2 bpm at therapeutic doses. These averages obscure individual outliers. In pooled amphetamine data reviewed by the FDA's 2006 safety analysis, roughly 5 to 7% of patients experienced clinically meaningful blood pressure elevations exceeding 10 mmHg. [5]

For a 68-year-old patient with stage 1 hypertension already on amlodipine, a 10 mmHg SBP increase could push them from controlled into uncontrolled range, directly increasing stroke and MI risk. The Framingham Heart Study cohort demonstrated that each 10 mmHg increment in SBP above 115 mmHg doubles the risk of a cardiovascular event in patients over 60. [6]

Arrhythmia Considerations

Amphetamines prolong the QTc interval modestly in some patients and increase sympathetic tone, which may trigger supraventricular tachycardias. Atrial fibrillation affects approximately 9% of adults over 65 in the United States. Prescribers should obtain a baseline ECG before initiating Vyvanse in any geriatric patient with a prior arrhythmia history, structural heart disease, or a QTc above 450 ms. This recommendation aligns with the American Heart Association's scientific statement on stimulant cardiovascular effects. [7]

Monitoring Protocol

Blood pressure and heart rate should be measured at baseline, at two weeks, and at every dose increase. Any resting heart rate above 100 bpm or SBP above 150 mmHg that persists across two readings warrants dose reduction or discontinuation. This threshold is more conservative than the standard adult approach precisely because the absolute risk is higher in older patients.

ADHD in Older Adults: What the Evidence Actually Shows

ADHD does not disappear at retirement. Population estimates suggest 2.5 to 4.5% of adults over 60 carry a diagnosable ADHD condition, though underdiagnosis is common because the disorder was rarely recognized in childhood for current cohorts of 65-year-olds. A 2021 systematic review in JAMA Network Open (N=8 studies, pooled sample over 6,000 older adults) found that ADHD symptom burden in older adults predicted significantly worse executive function and quality-of-life outcomes compared with age-matched controls. [8]

Absence of Dedicated Geriatric Trials

No phase 3 randomized controlled trial of Vyvanse has enrolled a primary cohort of patients 65 and older. The key ADHD trials that supported approval (studies SPD489-301, SPD489-302, SPD489-303) enrolled adults 18 to 55 years. Patients over 65 were excluded or present only as outliers in post-hoc subgroups too small to draw conclusions from. This is a meaningful evidence gap, not a minor footnote.

Clinicians must therefore extrapolate from mixed-age adult data and from the smaller literature on methylphenidate in older adults. A 2022 Cochrane review of stimulants in adults with ADHD found moderate-quality evidence for symptom improvement but noted that no included trial adequately represented patients over 60. [9]

Cognitive Aging and Stimulant Use

Amphetamines enhance dopaminergic and noradrenergic signaling in prefrontal circuits. These same circuits thin with normal aging, and the density of D1 and D2 receptors in the striatum declines by approximately 8% per decade after age 20, based on PET imaging studies. Whether stimulants provide equivalent cognitive benefit in a brain with age-reduced receptor density is biologically uncertain. [10]

The risk of worsening anxiety, insomnia, and appetite suppression may be proportionally larger in older adults, who already face higher rates of all three conditions. Appetite suppression is especially concerning: unintentional weight loss in adults over 65 is associated with increased mortality risk even when baseline BMI is normal.

Binge Eating Disorder in Older Adults

Vyvanse holds FDA approval for moderate-to-severe binge eating disorder (BED) in adults. BED affects an estimated 1.0 to 1.6% of adults over 60, though the diagnosis is rarely pursued in this age group because clinicians often attribute disordered eating patterns to grief, depression, or loneliness rather than a primary feeding disorder. [11]

Trial Data and Generalizability

The key BED trials for Vyvanse, MCE116 and MCE117 (combined N=724), showed a reduction in binge eating days per week from a baseline of approximately 4.7 to 0.8 with lisdexamfetamine 50 to 70 mg versus 3.0 with placebo at 12 weeks. Mean age of participants was 36 years. Patients over 65 were not enrolled. [12]

The cardiovascular burden of BED treatment in older adults must be weighed against the metabolic harms of untreated BED, including obesity progression and type 2 diabetes risk. This is a genuinely difficult clinical calculation with no guideline-level resolution currently available.

Nutritional Monitoring

Any older adult receiving Vyvanse for BED should have weight recorded monthly, with a structured dietary assessment at 3 months. A loss exceeding 5% of body weight over 3 months warrants dose review, independent of BED response. Clinicians may also consider concurrent dietitian involvement, since appetite suppression from the drug can compound nutritional deficiencies already common in older adults, including B12, folate, and vitamin D insufficiency.

Drug Interactions Concentrated in the 65+ Population

The average Medicare beneficiary takes 4.5 prescription medications. Polypharmacy sharply increases the likelihood of clinically relevant interactions with lisdexamfetamine.

Monoamine Oxidase Inhibitors

MAOIs combined with amphetamines may produce hypertensive crisis. Selegiline, used for Parkinson's disease, and rasagiline carry this risk even at low doses. The prescribing contraindication is absolute: Vyvanse must not be used within 14 days of any MAOI. Given that Parkinson's disease prevalence reaches 1 to 2% in adults over 65, this interaction is not rare. [13]

Antihypertensives and Diuretics

Amphetamines antagonize the antihypertensive effects of guanethidine, bethanidine, and reserpine. They can also reduce the efficacy of some beta-blockers by competing for peripheral adrenergic receptors. In older adults whose blood pressure control depends on a multi-drug regimen, adding a stimulant may silently erode that control without an obvious new symptom.

Urinary Acidifiers and Alkalinizers

Ascorbic acid (vitamin C) in doses above 1,000 mg daily acidifies urine and increases amphetamine excretion, potentially reducing therapeutic effect. Sodium bicarbonate or acetazolamide alkalinizes urine and raises amphetamine plasma levels. Both agents are used in older adults for reasons unrelated to ADHD, so a full medication and supplement inventory is necessary before dosing decisions are finalized. The interaction mechanism is described in the Vyvanse FDA label Section 7. [14]

Dosing Framework for Patients 65 and Older

No FDA-approved geriatric dosing schedule exists specifically for patients 65 and older, because no dedicated trials have been conducted. The framework below synthesizes the FDA label's renal-impairment guidance, the AGS Beers Criteria 2023 recommendations, and the pharmacokinetic principles described above.

Step 1: Pre-prescribing workup

• Obtain serum creatinine and calculate eGFR using the CKD-EPI equation.
• Record baseline blood pressure, heart rate, weight, and a 12-lead ECG if any cardiac history exists.
• Perform a full medication reconciliation, flagging all MAOIs, antihypertensives, urinary pH-altering agents, and serotonergic drugs.
• Screen for anxiety disorders, active insomnia, and unintentional weight loss in the prior 6 months.

Step 2: Starting dose

• Begin at 20 mg orally every morning regardless of the target dose in a younger adult.
• Avoid evening or afternoon dosing; the 10 to 13 hour half-life of d-amphetamine, extended further by reduced renal clearance, will disrupt sleep if taken after noon in most older patients.

Step 3: Titration

• Increase by 10 to 20 mg increments no faster than every 3 to 4 weeks.
• Recheck blood pressure and heart rate before each increase.
• For eGFR 15 to 29 mL/min/1.73 m², do not exceed 50 mg/day per the FDA label.
• For eGFR <15 mL/min/1.73 m², do not exceed 30 mg/day.

Step 4: Ongoing monitoring

• Monthly weight for the first 3 months.
• Blood pressure and heart rate at 2 weeks post-titration and then quarterly.
• Annual reassessment of continued benefit using a validated symptom scale (CAARS-S for ADHD or YBOCS-BE for BED).
• Document functional improvement, not just symptom scores, at each visit.

The 2023 AGS Beers Criteria explicitly lists CNS stimulants in the "use with caution" category for older adults because of their potential to worsen cardiovascular disease, anxiety, and anorexia. The criteria state: "CNS stimulants: Avoid in older adults with history of falls or fractures." [15]

Cognitive and Neuropsychiatric Effects Specific to Aging

Dementia and Cognitive Impairment

Stimulants are occasionally used off-label to address apathy and attention deficits in mild cognitive impairment (MCI) and early dementia. The evidence base is limited. A 2021 Cochrane review of methylphenidate for apathy in Alzheimer's disease found modest short-term benefit on apathy scales but no functional improvement and a signal of increased cardiovascular adverse events. [16] Direct lisdexamfetamine data in dementia populations do not exist.

Prescribing Vyvanse to a patient with undiagnosed or early-stage dementia carries the risk of precipitating psychosis, a known class effect of amphetamines. Older adults with Lewy body dementia are particularly vulnerable to drug-induced psychosis from dopaminergic agents.

Anxiety, Insomnia, and Falls

The sympathomimetic effects of amphetamines increase anxiety in susceptible individuals. In a pooled analysis of adult Vyvanse trials, insomnia was reported in 13% of patients on active drug versus 3% on placebo. Sleep disruption in older adults increases fall risk, and falls remain the leading cause of injury death in the 65 and older population in the United States, according to CDC injury data. [17]

Any new or worsened insomnia within the first 4 weeks of Vyvanse initiation in an older patient should prompt dose reduction before any sleep pharmacotherapy is added.

What Prescribers and Patients Should Know Before Starting

The absence of dedicated geriatric trial data does not mean Vyvanse is categorically inappropriate for adults over 65. It means prescribers must build more of the evidence architecture themselves, through careful baseline assessment, structured titration, and documented monitoring. Some older adults with ADHD who were never diagnosed in childhood experience meaningful quality-of-life improvements with treatment. The therapeutic opportunity is real.

The risk is also real. Cardiovascular events, appetite suppression leading to sarcopenic weight loss, drug-drug interactions in a polypharmacy context, and sleep disruption are not theoretical concerns. They are documented pharmacological consequences that occur at higher baseline rates in this age group.

A shared decision-making conversation should cover the absence of age-specific trial data, the cardiovascular monitoring plan, the renal-impairment dosing ceiling, and the planned reassessment timeline. Patients deserve to know that prescribing here is evidence-informed extrapolation, not evidence-confirmed standard of care. A 2023 position paper from the European ADHD Guidelines Group in Neuroscience and Biobehavioral Reviews recommended that stimulant prescribing in adults over 60 include a formal cardiovascular risk stratification using the ESC SCORE2-OP tool before initiation. [18]